From Rough Stretch to Breakthrough Era: Trade 5 of Biotech's Leading Stocks With 2X Daily Leverage

This is sponsored content. Barchart is not endorsing the websites or products set forth below.

The biotechnology sector is one of the most volatile in the market for good reason. Clinical trial outcomes, FDA decisions, patent expirations, and acquisition activity can send individual stocks up or down dramatically in a single session. That volatility creates risk, but for active traders, it also creates opportunity.

Biotech stocks had a difficult stretch from 2021 through 2024, as investor appetite for speculative assets cooled and capital rotated elsewhere. But since then, conditions have shifted. M&A activity in the sector has accelerated, with major pharmaceutical companies acquiring aggressively to offset looming patent cliffs. Clinical innovation in oncology, gene therapy, immunology, and rare disease continues to advance. 

With earnings season now underway for several of the sector's leading stocks, near-term catalysts are abundant, and the Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU) offers traders an effective way to act on that volatility with 200% daily leveraged exposure to five leading biotech stocks in a single ticker.

Direxion's Titans ETFs: Concentrated Sector Exposure With 2X Leverage

Direxion launched its Titans Leveraged & Inverse ETFs in October 2025, built around a straightforward premise: outsized sector performance tends to concentrate among a handful of leading stocks. The Titans series captures that dynamic by targeting the top five companies in key industries with equal-weighted, leveraged exposure, offering more precision than broad sector funds without the concentrated single-stock risk of individual name plays.

TBXU tracks the NYSE Biotechnology Top 5 Equal Weight Index, which selects the five leading biotechnology stocks from the broader NYSE Biotechnology Index. Each holding carries an equal 20% weight, and the index reconstitutes quarterly based on market capitalization. As of the most recent rebalancing, the five holdings are:

• Argenx (ARGX): an immunology-focused biotech developing treatments for serious autoimmune diseases
• Regeneron Pharmaceuticals (REGN): a biopharmaceutical company with a broad portfolio spanning eye disease, cancer, and inflammatory conditions
• Gilead Sciences (GILD): a leading antiviral and oncology platform best known for its dominant HIV franchise
• Amgen (AMGN): a global biotech focused on oncology, cardiovascular, and rare disease with a deep commercial portfolio
• Vertex Pharmaceuticals (VRTX): a dominant cystic fibrosis franchise now expanding into pain management, renal disease, and gene therapy

These five stocks represent a cross-section of biotech's most active therapeutic areas. Each carries meaningful near-term catalysts in the form of earnings reports, pipeline readouts, and regulatory decisions, the kinds of events that make biotech one of the most actively traded sectors in the market.

Biotech's Volatility Is the Trading Opportunity

Biotech stocks move on catalysts that few other industries experience at the same frequency or magnitude. FDA approval decisions, clinical trial results, and acquisition rumors can generate significant price action in a single session. That volatility is inherent to the sector and creates the kind of short-term trading opportunities that leveraged instruments are designed to amplify.

Managing exposure across multiple high-volatility stocks demands constant attention. Each has its own pipeline timeline, regulatory calendar, and earnings date. TBXU consolidates that exposure into a single position. The equal-weighted structure ensures that no single stock dominates the fund's performance, as each of the five holdings contributes proportionally to the index return that TBXU then seeks to double.

Trading Biotech With 2X Daily Leverage

The Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU) seeks 200% of the daily performance of the NYSE Biotechnology Top 5 Equal Weight Index, before fees and expenses.

• When the index rises 1%, TBXU targets a 2% gain (before fees)
• When the index falls 1%, TBXU targets a 2% decline (before fees)
• No need to manage margin across five separate positions

TBXU resets its leverage exposure daily. The 2X target applies to single-day index movements, and holding the fund beyond a single day introduces compounding effects. It is designed for short-term tactical trading, not long-term holds.

Capture Biotech's Earnings Volatility in a Single Trade

Biotech is entering one of its highest-catalyst stretches of the year. Several of the sector's leading stocks are reporting earnings, with additional pipeline readouts and regulatory decisions expected throughout the calendar year. Each event carries meaningful price risk in either direction, exactly the environment that active traders look to position around.

For traders who want to act on a directional view of the biotech sector without managing five separate entries, exits, and position sizes across five individual stocks, the Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU) offers a more direct path. TBXU provides 200% daily leveraged exposure to the sector's leading stocks in a single trade.

Leveraged and inverse ETFs pursue daily leveraged investment objectives, which means they are riskier than alternatives that do not use leverage. They seek daily goals and should not be expected to track the underlying index over periods longer than one day. They are not suitable for all investors and should be utilized only by sophisticated investors who understand leverage risk and who actively manage their investments.

Daily leveraged ETFs reset exposure each day. They seek daily investment results and should not be expected to track the underlying index over periods longer than one day.

An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a Fund’s prospectus and summary prospectus call 866-476-7523 or visit our website at direxion.com. A Fund’s prospectus and summary prospectus should be read carefully before investing.

Direxion ETF Risks – An investment in the Fund involves risk, including the possible loss of principal. The Fund is non-diversified and includes risks associated with the Fund concentrating its investments in a particular industry, sector, or geographic region which can result in increased volatility. The use of derivatives such as futures contracts and swaps are subject to market risks that may cause their price to fluctuate over time.

Biotechnology Industry Risk – Companies within the biotechnology industry are subject to the risks of heavy investment in research and development to varying degrees of success, rapid obsolescence, significant governmental regulation and changes to governmental policies or the need for regulatory approvals, which may delay or inhibit the release of new products.

Healthcare Sector Risk — The profitability of companies in the healthcare sector may be affected by extensive, costly and uncertain government regulation, rising costs of medical products and services, changes in the demand for medical products and services, an increased emphasis on outpatient services, limited product lines, industry innovation and/or consolidation, changes in technologies and other market developments.

Distributor: ALPS Distributors, Inc.

The above is sponsored content. Barchart was paid up to two hundred eighty eight thousand dollars for placement and promotion of the content on this site and other forms of public distribution covering the period of January - June 2026.  For more information please view the Barchart Disclosure Policy here.